Table 1.
Baseline Clinical Characteristics of the Study Patients
| Overall Patients (n=277) (n,%) | Non-COPD (n=194) (n,%) | COPD (n=83) (n,%) | p-value | |
|---|---|---|---|---|
| Sex | ||||
| Female | 124 (44.8) | 100 (51.5) | 24 (28.9) | 0.001 |
| Age (year) | 64.9±11.2 | 61.8±10.8 | 72.0±8.4 | <0.001 |
| Median survival time (months) | 19.6 [15.5–23.7] | 21.3 [16.7–25.8] | 10.7 [7.2–14.1] | 0.019 |
| Stage | 0.104 | |||
| IIIB | 20 (7.2) | 11 (5.7) | 9 (10.8) | |
| IV | 257 (92.8) | 183 (94.3) | 74 (89.2) | |
| BMI (kg/m2) | 23.3±3.5 | 23.7±3.5 | 22.6±3.3 | 0.027 |
| EGFR mutation | 92 (34.5)* 267 tested | 71 (38.0)* 187 tested | 21 (26.2)* 80 tested | 0.065 |
| First-line treatment | 0.064 | |||
| Conventional chemotherapy | 166 (59.9) | 113 (58.3) | 53 (63.8) | |
| Targeted therapy | 68 (24.5) | 53 (27.3) | 15 (18.1) | |
| Supportive care only | 33 (11.9) | 18 (9.3) | 15 (18.1) | |
| Smoking | <0.001 | |||
| Never smoker | 149 (53.8) | 119 (61.7) | 30 (36.1) | |
| Ever smoker | 127 (45.8) | 74 (38.3) | 53 (63.9) | |
| ECOG | 0.001 | |||
| 0–1 | 236 (85.5) | 174 (90.2) | 62 (74.7) | |
| 2–3 | 40 (14.5) | 19 (9.8) | 21 (25.3) | |
| Pathology | 0.043 | |||
| Non-squamous | 246 (88.8) | 177 (91.2) | 69 (83.1) | |
| Squamous | 31 (11.2) | 17 (8.8) | 14 (16.9) | |
| FEV1 (liter) | 2.0±1.5 | 2.0±0.7 | 1.9±2.5 | 0.845 |
| FEV1 (% predicted) | 78.8±22.4 | 82.7±22.3 | 69.9±20.0 | <0.001 |
| FVC (liter) | 2.7±2.0 | 2.5±0.9 | 3.0±3.3 | 0.195 |
| FVC (% predicted) | 77.7±21.8 | 76.9±21.3 | 79.5±23.1 | 0.381 |
| FEV1/FVC (% predicted) | 74.0±11.1 | 79.4±6.7 | 61.3±8.7 | <0.001 |
| DLCO (abs) | 12.4±4.6 | 13.1±4.7 | 10.8±3.9 | <0.001 |
| DLCO (%) | 70.2±20.0 | 71.7±19.7 | 66.8±20.3 | 0.079 |
| NLR | 4.07±3.49 | 4.05±3.72 | 4.13±2.92 | 0.841 |
| PLR | 189.6±86.1 | 189.3±87.2 | 190.2±84.0 | 0.940 |
| CRP | 3.74±0.42 | 3.55±0.49 | 4.13±0.81 | 0.259 |
| Hemoglobin (g/dl) | 13.0 [12.0–14.0] | 13.0 [12.0–14.0] | 13.0 [11.7–14.3] | 0.400 |
Note: *Only patients who are tested were considered.
Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, c-reactive protein; BMI, body mass index; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio.